Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

S Iliodromiti, a,b, W Wang, c, MA Lumsden, b MS Hunter, d R Bell, e G Mishra, f M Hickey, g
the International COMMA (Core Outcomes in Menopause) Consortium

a Women’s Health Division, Blizard Institute, Queen Mary University London, London, UK
b School of Medicine, University of Glasgow, Glasgow, UK
c Department of Obstetrics, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
4 Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
d Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
e Faculty of Medicine, School of Public Health, University of Queensland, Brisbane, Australia
f Department of Obstetrics and Gynaecology, University of Melbourne and The Royal Women’s Hospital, Victoria, Australia

Correspondence: S Iliodromiti, Women’s Health Research Unit, Centre for Primary Care and Public Health, Queen Mary University of London, Yvonne Carter Building, 58 Turner Street, London E1 2AB, UK. Email: s.iliodromiti@qmul.ac.uk

Accepted 10 October 2019. Published Online 13 November 2019.

Background There is substantial variation in how menopausal vasomotor symptoms are reported and measured among intervention studies. This has prevented meaningful comparisons between treatments and limited data synthesis.

Objectives To review systematically the outcome reporting and measures used to assess menopausal vasomotor symptoms from randomised controlled trials of treatments.

Search strategy We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to May 2018.

Selection criteria Randomised controlled trials with a primary outcome of menopausal vasomotor symptoms in women and a sample size of at least 20 women per study arm.

Data collection and analysis Data about study characteristics, primary vasomotor-related outcomes and methods of measuring them.

Main results The search identified 5591 studies, 214 of which were included. Forty-nine different primary reported outcomes were identified for vasomotor symptoms and 16 different tools had been used to measure these outcomes. The most commonly reported outcomes were frequency (97/214), severity (116/214), and intensity (28/114) of vasomotor symptoms or a composite of these outcomes (68/214). There was little consistency in how the frequency and severity/intensity of vasomotor symptoms were defined.

Conclusions There is substantial variation in how menopausal vasomotor symptoms have been reported and measured in treatment trials. Future studies should include standardised outcome measures which reflect the priorities of patients, clinicians, and researchers. This is most effectively achieved through the development of a Core Outcome Set. This systematic review is the first step towards development of a Core Outcome Set for menopausal vasomotor symptoms.

Keywords Core outcomes, menopause, randomised clinical trials, vasomotor symptoms.

Introduction

There is general agreement that vasomotor symptoms (hot flushes and night sweats) are the most common and problematic menopausal symptom.1,2 Vasomotor symptoms are also the leading patient priority for treatment.3 Oestrogen-containing menopausal hormone therapy (MHT) is an effective treatment for menopausal vasomotor symptoms; however, use of MHT has fallen substantially following concerns about safety.4 There is a growing focus on the development and evaluation of nonpharmacological and nonhormonal treatments for vasomotor symptoms.5 In

*Joint first authors.
addition, MHT is contraindicated in women with a personal history of breast cancer who may report more severe vasomotor symptoms than women experiencing natural menopause. Enhanced understanding of the central mechanisms regulating vasomotor symptoms is driving the development and evaluation of novel targeted therapies, but the interpretation and implementation of these studies is hampered by lack of consensus about how vasomotor symptoms should be reported and measured. This limits the potential to compare treatments and to synthesise the evidence, which in turn compromises decision-making by clinicians and patients.

Current National Institute for Health and Care Excellence (NICE) guidelines on the management of menopause highlight the need for greater standardisation of outcome reporting and measures for treatment trials in menopause, and the consequent difficulty in evidence synthesis. There is an urgent need to determine what outcomes are most important to patients, clinicians, and researchers in order to increase the relevance of future intervention studies and facilitate comparisons between treatments. The Core Outcomes in Effectiveness (COMET) initiative is leading protocols for the development of Core Outcome Sets. These are well defined, condition-specific, and feasible outcomes which should be included as a minimum set of outcomes in intervention studies. To advance the development of Core Outcome sets in women’s health, 80 editors of women’s health journals have formed a consortium to support the development, dissemination, and implementation of core outcome sets within the reproductive field (Core Outcomes in Women’s and Newborn Health-CROWN, http://www.crown-initiative.org). The Core Outcomes in Menopause (COMMA) initiative is an international consortium of clinicians, researchers, and consumers developing a Core Outcome Set for menopausal symptoms. Following a standardised process, we have first systematically reviewed all randomised controlled trials (RCTs) of interventions for menopausal vasomotor symptoms to determine what outcomes have been reported and how they have been measured. We will then repeat this process for vaginal symptoms at menopause. This information will then be used to inform a Delphi survey by clinicians, researchers, and patients to identify priorities for inclusion in the final Core Outcome Set.

Methods

Study eligibility
We included all RCTs with a primary outcome of female menopausal vasomotor symptoms and a sample size of at least 20 women per study arm to minimise the likelihood of including feasibility or pilot studies. We excluded studies that assessed menopausal vasomotor symptoms as a secondary outcome, quasi-randomised studies, secondary analyses of previously published RCTs, conference abstracts of RCTs, observational, analytical, or diagnostic studies and feasibility/pilot studies. We also excluded studies primarily aiming to assess pharmacokinetics, the mechanism of drug action, or tolerability and intervention studies with no explicit sample size calculations.

Search strategy
We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) until May 2018. We hand-searched the reference lists of the included trials or other keynote publications. Search terms included menopause, menopausal, menopausal symptoms, climacteric, hot flush or flash, night sweat, vasomotor, and a search filter for RCTs (Appendix S1). There was no language restriction.

Data extraction
Two reviewers (W.W.L. and S.I.) independently assessed the studies using the predefined criteria described above. Disagreement was resolved by discussion with the steering committee. Full articles were obtained and data were extracted using a prespecified extraction sheet.

Quality assessment
Jadad scoring was used for assessing the methodological quality of the included trials. The 5-point validated scoring system assesses the following: whether the trial (1) was described as randomised (1 point), (2) used an appropriate method of randomisation (1 point), (3) was blinded (1 point), (4) used an appropriate method of blinding (1 point), and (5) accounted for all patients randomised (1 point); ≤2 points was considered low quality and ≥3 was considered medium to high quality.

The quality of describing and reporting the outcome was assessed using the 6-point Management of Otitis Media with Effusion in Cleft Palate (MOMENT) scoring criteria, which has been used previously in the context of quality assessment of studies for the development of a core outcome set and a cut-off of ≥4 to indicate a high-quality trial. The following points were considered: whether the primary outcome was (1) clearly stated (1 point), (2) clearly defined (1 point); whether the secondary outcomes were (3) clearly stated (1 point), (4) clearly defined (1 point); (5) whether the authors explained the use of the outcomes they selected (1 point); (6) whether specific methods were used to enhance the quality of outcome measurement (1 point).

Patient involvement
Patients were not involved in the stage of conducting the systematic review but they will be involved in the subsequent steps (Delphi and consensus meeting) of developing the core outcome set.
Core outcomes
Core outcomes do not exist in this research field and were therefore not used in the systematic search. Our aim is to develop and disseminate core outcomes of menopausal symptoms and this systematic review is the first step of the process.

Funding
This study was funded by an MRC postdoctoral fellowship (S.I., MR/N015177/1), NHMRC Practitioner Fellowship (MH, APP 1058935) and an NHMRC Principal Research Fellowship (G.D.M., APP1121844). The funders were not involved in any stage of conducting this systematic review.

Results
The search identified 5591 studies, of which 2711 duplicates were removed. We screened 2880 titles and abstracts and excluded 2372 records which did not meet the inclusion criteria. In all, 544 studies were read in full. Of these, 330 were excluded; 59 included fewer than 20 women per study arm and 54 were not an RCT; 126 did not clearly state a sample size calculation; 52 did not measure vasomotor symptoms as the primary outcome; 39 were secondary analysis. Following these exclusions, 214 RCT were included (Figure 1). Table S1 describes the 214 studies with a total of 22 682 participants. The studies were published between 1994 and 2018. More than one-third of the trials (77/214, 36%) were conducted in USA. The follow-up period ranged from 4 to 52 weeks, with half the included studies following up participants for 12 weeks (108/214, 50%).

Reported outcomes
The included trials reported 31 different interventions for menopausal vasomotor symptoms: 68 (32%) included hormone therapies and the remaining 146 nonhormonal therapies; 46 were prescription therapies; and 100 were nonprescription therapies. Among these interventions, estrogen and/or progestogen therapies (61/214, 29%) and over-the-counter dietary or herbal supplements (68/214, 32%) were the most common interventions (Table 1).

Forty-nine primary outcomes were identified from 214 RCTs including 22 682 women. Almost half of the RCTs (94/214, 44%) only included postmenopausal women, 12% (26/214) only included women with a history of breast cancer, and 5% (12/214) included peri- and postmenopausal women. Around a quarter of the RCTs (56/214, 26%) included both surgical and naturally peri- and postmenopausal women. We categorised the primary outcomes into four domains: (1) purely vasomotor-related outcomes (183/214, 86%); (2) quality-of-life-related outcomes (9/214, 4%); (3) other outcomes (7/214, 3.2%); and (4) safety outcomes (71/214, 33%).

Figure 1. Flowchart of search strategy.
Nine trials assessed quality of life and five trials assessed interference as primary outcomes (Table 2).

### Measurement tools

Seven different measurement tool categories were used to measure purely vasomotor-related outcomes. Most (158/214, 74%) included trials used diary records of vasomotor symptoms and 24.7% (53/214) used menopause-specific subscales. Of these subscales, the Kupperman Menopausal Index (25/57, 44%), Greene Climacteric Scale (15/57, 26%), and Menopause Rating Scale (MRS) (10/57, 18%) were the three most frequently used measurement tools. The Hot Flush Rating Scale (HFRS) measures how vasomotor symptoms interfere with daily routine and activities. The Hot Flush Related Daily Interference (HFRDIS) and the shortened Hot Flush Interference (HFI) scale have been used to measure interference due to vasomotor symptoms but were not the primary outcome of eligible RCTs, and so were not included in the systematic review. However, they will still be used for the subsequent Delphi process. Other subjective vasomotor symptoms measurement tools included a 20-item structured symptom checklist; two of the items asking about the presence of hot flushes and cold/night sweats, a 5-point (from none to very severe) scoring system about the severity of hot flushes and night sweats, Interactive Voice Response System to record the number and severity of the hot flushes, and self-reported surveys. Objective measures of vasomotor symptoms such as skin conductance were used in five trials in addition to subjective measures (Table 3).

Diaries were used to record 25 different types of menopausal vasomotor-related outcomes and accounted for 57% (25/44) of all primary outcomes. The number, frequency, severity, and intensity of menopausal vasomotor symptoms were the most commonly reported vasomotor-related outcomes assessed by diaries. However, there was substantial variation in the definitions of each outcome. For example, for frequency, the majority of included studies (72/214) reported the 'number of vasomotor symptoms per 24 h' (8 retrospectively and 64 prospectively), and 39/214 measured the 'number of vasomotor symptoms per week'. Table S2 shows the complete list of vasomotor-related outcomes recorded by diaries and how often they have been reported in RCTs of intervention studies for vasomotor symptoms.

Quality of life outcomes was measured by three scales: Menopausal-Specific Quality of Life (MENQOL) and Women’s Health Questionnaire (WHQ), and the European Organisation for Research and Treatment of Cancer Quality of Life-Care30 (EORTC QLQ-C30). Of these, 14 of 15 trials chose menopausal-specific scales (MENQOL, WHQ). Only

### Table 1. Interventions for menopausal vasomotor symptoms

| Interventions                                      | Trials, n (%) |
|---------------------------------------------------|---------------|
| Hormone therapy                                   |               |
| Estrogen alone                                    | 68 (32)       |
| Estrogen + progesterone                           | 45            |
| Estrogen + bazedoxifene                           | 12            |
| Progesterone alone                                | 1             |
| Tibolone                                          | 4             |
| Nonhormonal therapy                               |               |
| Prescription therapies                            | 46 (21)       |
| SSRIs/SNRIs                                       | 26            |
| Antiepileptic                                     | 10            |
| ERr 731                                           | 2             |
| BRN-01                                            | 1             |
| Cinnarizin                                        | 1             |
| Gamolenic acid                                    | 1             |
| L-isoleucine                                      | 1             |
| MF 101                                            | 1             |
| Neurokinin 3                                      | 1             |
| Oxybutynin                                        | 1             |
| RAD 1901                                          | 1             |
| Nonprescription therapies                         | 100 (47)      |
| Over-the-counter dietary and/or herbal products   | 68            |
| Acupuncture                                       | 8             |
| Exercise                                          | 5             |
| Lifestyle education                               | 4             |
| Relaxation                                        | 3             |
| Paced respiration                                 | 3             |
| Cognitive therapy/cognitive behaviour therapy     | 4             |
| Mindfulness training                              | 2             |
| Guasha                                            | 1             |
| Local thermal therapy                             | 1             |
| Clinical hypnosis                                 | 1             |
| Total RCTs                                        | 214           |

MF 101, Menopausal Formula 101; RCTs, randomised controlled trials; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin and norepinephrine reuptake inhibitors. ERr 731: A special extract from the roots of Rheum rhaponticum, referred to as ERr 731 (tradename Phytoestrol N). BRN-01: A homeopathic medicine registered in France for menopausal hot flushes, combining the five homeopathic medications: Actaea racemosa (4 centesimal dilutions [4CH]), Arnica montana (4CH), Glonoainum (4CH), Lachesis mutus (5CH), and Sanguinaria canadensis (4CH). RAD1901: An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM).
one trial including women with vasomotor symptoms after breast cancer used a general QOL scale (EORTC QLQ-C30)\(^{136}\) (Table 3).

**Variation in the definitions of vasomotor-related outcomes**

There was substantial heterogeneity in the definition of vasomotor-related outcomes. Three different definitions were used to measure the frequency of vasomotor symptoms. Most studies (79/97, 81%) defined frequency as the number of hot flushes or night sweats, whereas 18 studies did not define how frequency was measured. The severity of vasomotor symptoms was defined in nine different ways and the intensity in seven different ways (Table S3). The 68 studies reporting composite outcomes for vasomotor symptoms utilised 11 different ways of defining the composite score. The most commonly used approach (27/68, 40%) measured the number of hot flushes and night sweats, and calculated a composite score weighted by severity rating. There was considerable overlap between composite score definitions.

**Quality assessment of trials**

Regarding methodological quality, 34% (73/214) of included RCTs scored 5 out of 5 points on the Jadad scale. More than half of the trials (118/214, 55%) scored 6 out of 6 points on the MOMENT scale (Table S1).
Variation in reported menopausal vasomotor symptoms

Table 3. Tools for measuring vasomotor-related outcomes

| Tools                                      | n   |
|--------------------------------------------|-----|
| Purely vasomotor symptoms                 |     |
| Hot flushes diary/electronic diary         | 158 |
| Menopausal-specific scale                  | 53  |
| Kupperman Menopausal Index (KMI)           | 25  |
| Greene Climacteric Scale (GCS)             | 15  |
| Menopause Rating Scale (MRS)               | 10  |
| Wiklund Vasomotor Symptom Subscale score   | 1   |
| Perceived Perimenopausal Disturbances Scale| 1   |
| Simplified Menopausal Index (SMI)          | 1   |
| Structured menopausal-specific checklist   | 1   |
| Skin conductance monitor system            | 5   |
| Interactive voice system                   | 1   |
| Symptoms scoring system                    | 1   |
| Self-reported validated survey instruments | 1   |
| Quality of life                            |     |
| MENQOL                                     | 15  |
| WHQ                                        | 12  |
| EORTC QLQ-C30                              | 2   |
| Interference                               |     |
| The Hot Flush Rating Scale (HFRS)          | 5   |

Discussion

Main findings
This is the first systematic review of outcomes used to measure vasomotor symptoms in randomised controlled trials of interventions. Our findings demonstrate major inconsistencies in how treatments for the same symptoms have been evaluated. For example, the severity of hot flushes and night sweats had nine different definitions. Overall, the most commonly used outcomes for vasomotor symptoms (based on 214 RCTs including 22,682 women) were the frequency and intensity of vasomotor symptoms or a compound measure of these (n = 59). A smaller number of studies (n = 5) took a different approach and measured the interference due to vasomotor symptoms. It remains unclear which measures of vasomotor symptoms best reflect the priorities of patients, clinicians, and researchers, and this will be addressed by the development of a Core Outcome Set. Inclusion of the Core Outcome Set in future intervention studies for vasomotor symptoms will enhance the quality and relevance of trials and facilitate decision-making by clinicians and patients.

Strengths and limitations
We conducted a comprehensive search strategy with a robust methodological design to include all large (>20 participants per arm) RCTs of interventions for vasomotor symptoms. Two researchers independently evaluated the available evidence to minimise overlooking relevant evidence. To our knowledge, this is the first time that reported vasomotor-related outcomes have been synthesised, a necessary step to inform the Delphi process for key stakeholders to rate the components of the core outcome set.12 Although most included trials were of medium or high methodological standard, the diverse nature of the outcome measures used diminishes the value of these trials to inform patient choices and clinical decision-making.

This study focused on menopausal vasomotor symptoms in the first instance. We recognise that personal, ethnic, cultural, and geographical factors influence the nature and experience of menopause, and that not all women experience vasomotor symptoms at menopause.235 We comprehensively searched three major databases and it is unlikely we have missed an RCT published elsewhere. We acknowledge we did not search CINAHL, but we doubt that additional RCTs could only be identified in that database. We included randomised trials with vasomotor-related symptoms as a primary outcome with over 20 participants in each arm, excluding observational studies and pilot studies. However, given the large number of included studies, we do not anticipate that we have missed outcomes not captured in larger trials. We recognise that this systematic review was limited to trials where vasomotor symptoms were the primary outcome. However, given the large number of studies included, we do not consider that we missed important outcomes. The expert panel and Delphi process will highlight any additional important outcomes that may have been overlooked because they were not included in treatment studies or were reported as secondary outcomes. We also appreciate that our findings may be skewed towards FDA-driven outcomes, as many studies were conducted in USA. We have only listed the range of outcome measures used and have not applied any qualitative assessment of the value or importance of these measures for women or clinicians. Only a few relatively recent RCTs have measured the impact of interventions on the interference caused in women by vasomotor symptoms and it is uncertain whether the frequency/severity or interference of symptoms best reflects women’s treatment priorities. These issues will be addressed by the Delphi survey and the subsequent consensus meeting. Most published RCTs of interventions for vasomotor symptoms focused on caucasian women who may experience menopause differently from other ethnicities.256 The COMMA consortium includes representation from a wide range of geographical areas and ethnic groups to ensure that the Core Outcome Set reflects variations in stakeholder priorities.

Interpretation
Inconsistency in measures used for the evaluation of treatments for vasomotor symptoms limits comparisons between treatments and the interpretation of findings for...
clinical practice. Understanding the efficacy of new treatments and how they compare with existing approaches requires the use of standardised outcome measures that are meaningful to patients, and feasible for clinicians and researchers.

A Core Outcome Set does not preclude the inclusion of additional outcome measures, but sets a minimum standard of outcomes that should be reported in all interventional trials. This systematic review is the first step towards the development of meaningful consensus by identifying how vasomotor symptoms have been measured to inform consensus through the Delphi process.

**Conclusion**

Most intervention studies for vasomotor symptoms have measured frequency or severity of symptoms, or a combination of both. Some have measured the interference caused in daily life due to symptoms. There is a need for consensus around the optimum outcomes and how these should be measured to facilitate comparisons between interventions and ensure patient-centred clinical practice.

**Disclosure of interests**

No conflict of interest to disclose. Completed disclosure of interest forms are available to view online as supporting information.

**Contribution of authorship**

MH and SI conceived the idea and set the protocol. GM, RN, and MAL refined the protocol. SI and WW conducted the systematic search, and SI wrote the first draft of the paper with contribution from WW in writing up the methods. MSH provided useful insight regarding the bothersome aspect of menopausal symptoms. All authors edited and accepted the manuscript prior to submission.

**Details of ethics approval**

No ethics approval was required as we have summarised already published data.

**Funding**

This study was funded by an MRC postdoctoral fellowship (S.I., MR/N015177/1), NHMRC Practitioner Fellowship (M.H., APP 1058935), and an NHMRC Principal Research Fellowship (G.D.M., APP1121844). The funders were not involved in any stage of this systematic review.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

---

**Table S1.** Study characteristics and quality assessment scoring of the included studies.

**Table S2.** Vasomotor-related outcomes measured by diary.

**Table S3.** Different definitions for frequency, severity, intensity, and vasomotor scores of vasomotor-related outcomes.

**Appendix S1.** Search strategy.

**References**

1. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. *Am J Public Health* 2006;96:1226–35.

2. National Institutes of Health National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. *Ann Intern Med* 2005;142:1003–13.

3. Carpenter JS, Woods NF, Otte JL, Guthrie KA, Hohenese C, Newton KM, et al. MsFLASH participants’ priorities for alleviating menopausal symptoms. *Climacteric* 2015;18:859–66.

4. Barrett-Conner E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. *Ann Rev Public Health* 2005;26:115–40.

5. Velentzas LS, Banks E, Siteas F, Salgarane U, Tan EH, Canfell K. Use of menopausal hormone therapy and bioidentical hormone therapy in Australian women 50 to 69 years of age: results from a national cross-sectional study. *PLoS One* 2016;11:e0146494.

6. Marino JL, Saunders CM, Emery U, Green H, Doherty DA, Hickey M. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? *Menopause* 2016;23:1000–8.

7. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNK (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. *Front Neuroendocrinol* 2013;34:211–27.

8. National Institute for Health and Care Excellence. Menopause: diagnosis and management NICE guidelines [NG23] 2015. https://www.nice.org.uk/Guidance/NG23

9. Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, et al. Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network. *Menopause* 2014;21:45–58.

10. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products To Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation. 2003. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf

11. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials* 2012;13:132.

12. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: version 1.0. *Trials* 2017;18:280.

13. Khan K. The CROWN Initiative: journal editors invite researchers to develop core outcomes in women’s health. *BJOG* 2014;121:1181–2.
Variation in reported menopausal vasomotor symptoms

14 Hirsch M, Duffy JMM, Kusznir JO, Davis CJ, Plana MN, Khan KS, et al. Variation in outcome reporting in endometriosis trials: a systematic review. Am J Obstet Gynecol 2016;214:452–64.
15 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
16 Harman NL, Bruce IA, Cally P, Tierney S, Sharif MO, O’Brien K, et al. MOMENT—Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials 2013;14:70.
17 Aghamiri V, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Nazemiyeh H. The effect of Hoo (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial. Complement Ther Clin Practice 2016;23:130–5.
18 Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol 2010;26:333–7.
19 Al-Akoum M, Maunsell E, Verreault R, Pronovost L, Otis H, Dodin S. Effects of Hypericum perforatum (St. John’s wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009;16:307–14.
20 Al-Azzawi F, Buckler H. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003;6:118–27.
21 Allaneh Z, Rouholamini S, Valaie S. Comparison of gabapentin with estrogen for treatment of hot flashes in post-menopausal women. J Res Pharm Pract 2013;2:62–4.
22 Anderson DJ, Seib C, McCarthy AL, Yates P, Porter-Steele J, McGuire A, et al. Facilitating lifestyle changes to manage menopausal symptoms in women with breast cancer: a randomized controlled pilot trial of The Pink Women’s Wellness Program. Menopause 2015;22:937–45.
23 Andrikoula M, Baker D, Nesic J, Liao L, Duka T, Prelevic G. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women. Climacteric 2011;14:544–50.
24 Archer D, Schmelter T, Schaefers M, Gerlinger C, Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17beta-estradiol for relief of hot flushes in postmenopausal women. Menopause 2014;21:227–35.
25 Archer D, Seidman L, Constantine G, Pickar J, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:e1–10.
26 Archer DF, DeAbate CA, Einhaus KB, Heuer MA, Kirkegard LW, Miller JD, et al. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003;10:516–21.
27 Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1–e10.
28 Asghari M, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Malakouti J, Nedjat S. Effect of aerobic exercise and nutrition education on quality of life and early menopausal symptoms: A randomized controlled trial. Women Health 2017;57:173–88.
29 Aslan E, Bagis T, Kilicdag E, Tarim E, Erkanli S, Kuscu E. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007;56:78–83.
30 Aso T, Uchiyama S, Matsumura Y, Taguchi M, Nozaki M, Takamatsu K, et al. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equal nonproducing postmenopausal Japanese women. J Women’s Health 2012;21:92–100.
31 Auerbach L, Rakus J, Bauer C, Gerner C, Ullmann R, Wimmer H, et al. Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial. Menopause 2012;19:426–32.
32 Avi N, Coeytaux R, Isom S, Prevette K, Morgan T. Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial. Menopause 2016;23:626–37.
33 Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): A randomized controlled trial. Menopause 2012;19:749–59.
34 Bacchi-Modena A, Bolis P, Campagnoli C, De C, Meschia M, Pansini F, et al. Efficacy and tolerability of (R)Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27:285–92.
35 Bachmann G, Crosby U, Feldman R, Ronkin S, Constantine G. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. Menopause 2011;18:508–14.
36 Bachmann G, Schaefers M, Uddin A, Utan W. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Br J Obstet Gynaecol 2007;110:771–9.
37 Bai W, Hennecke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus placebo. Maturitas 2007;58:31–41.
38 Barton DL, LaVasseur BL, Sloan JA, Stavis AN, Flynn KA, Dyar M, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278–83.
39 Benster B, Carey A, Wadsworth F, Vashish A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of prostegestelle progesterone cream on postmenopausal women. Menopause Int 2009;15:63–9.
40 Biglia N, Sgandurra P, Peano E, Marenco D, Moggio G, Bounous V, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric 2009;12:310–8.
41 Bokmand S, Flyger H. Acupuncture relieves menopausal discomfort in breast cancer patients: a prospective, double blinded, randomized study. Breast 2013;22:320–3.
42 Borud E, Alaiekt T, White A, Fonbeve V, Eggen A, Hammar M, et al. The acupuncture on hot flushes among menopausal women (ACUFLASH) study, a randomized controlled trial. Menopause 2009;16:848–93.
43 Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12–20.
44 Burke G, Legault C, Anthony M, Bland D, Morgan T, Naughton M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause 2003;10:147–53.
45 Buster J, Koltun W, Pascual M, Day W, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:1343–51.
46 Butt D, Lock M, Lewis J, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310–8.
Ilidromiti et al.

47 Carmignani LO, Pedro AO, Costa-Paiva LH, Pinto-Neto AM. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 2010;67:262–9.

48 Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause 2011;18:611–20.

49 Carpenter J, Burns D, Wu J, Otte J, Schneider B, Ryker K, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med 2013;28:193–200.

50 Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril 2012;97:399–404 e1.

51 Cezarino PY, Bagnoli VR, Fonseca AM, Soares JM, Baracat EC. The effects of cinnarizine on menopausal symptoms in women. Climacteric 2011;14:492–6.

52 Chandeeying V, Sangthawan M. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai 2007;90:1720–6.

53 Chang A, Kwak B, Yi K, Kim J. The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. Phytother Res 2012;26:510–6.

54 Chenoy R, Hussain S, Tayob Y, O’Brien PM, Moss MY, Morse PF. Carpenter J, Burns D, Wu J, Otte J, Schneider B, Ryker K, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med 2013;28:193–200.

55 Chien L, Liu S, Chang Y, Liu C. Local thermal therapy effects on climacteric symptoms in perimenopausal women: phase III study. J Altern Complement Med 2011;17:1133–40.

56 Chung DJ, Kim HY, Park KH, Jeong KA, Lee SK, Lee YI, et al. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J 2007;48:289–94.

57 Cohen L, Joffe H, Guthrie K, Ensrud K, Freeman M, Carpenter J, et al. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Maturnpause 2014;21:347–54.

58 Colau JC, Vincent S, Marijnens P, Allaert FA. Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial. Drugs R D 2012;12:107–19.

59 Cortés-Bonilla M, Bernardo-Escudero R, Alonso-Campero R, Francisco-Doce M, Hernández-Valencia M, Celis-Gonzalez C, et al. Treatment of menopausal symptoms with three low-dose continuous sequential 17b-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology. Gynecol Endocrinol 2015;31:552–9.

60 Daley A, Thomas A, Roalle A, Stokes-Lampard H, Coleman S, Rees M, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG 2015;122:565–75.

61 Davinelli S, Scapagnini G, Marzatico F, Nobile V, Ferrara N, Corbi G. Influence of equal and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas 2017;96:77–83.

62 Davis SR, Briganti EM, Chen RQ, Dalais FS, Bailey M, Burger HG. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. A randomised controlled trial. Med J Aust 2001;174:68–71.

63 de Luca AC, da Fonseca AM, Lopes CM, Bagnoli VR, Soares JM, Baracat EC. Acupuncture-ameliorated menopausal symptoms: single-blind, placebo-controlled, randomized trial. Climacteric 2011;14:140–5.

64 de Vrijer B, Snijders MP, Troostwijk AL, The S, Iding RJ, Friese S, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women. Maturitas 2000;34:47–55.

65 del Giorno C, Fonseca AM, Bagnoli VR, Assis JS, Soares JM Jr, Baracat EC. Effects of Trifolium pratense on the climacteric and sexual symptoms in postmenopausal women. Rev Assoc Med Bras 2010;56:558–62.

66 Duijts SF, van Beurden M, Oldenburg HS, Hunter MS, Kieffer JM, Stuiver MM, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30:4124–33.

67 Ee C, Yue C, Chondros P, Myers SP, French SD, Teede H, et al. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med 2016;164:146–54.

68 Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. Menopause 2013;20:291–8.

69 Endrikat J, Graeser T, Mellingen U, Ertan K, Holz C. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women. Maturitas 2007;58:201–7.

70 Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas 2011;68:189–96.

71 Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161–6.

72 Faure ED, Chartre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329–34.

73 Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage 2008;35:397–405.

74 Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res 2009;35:1083–90.

75 Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al. Efficacy of escitalopram for hot flushes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267–74.

76 Frei-Kleiner S, Schaffner W, Rahiffs VW, Bodmer C, Birkhauser M. Cimicifuga racemosa dried ethanol extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51:397–404.

77 Fu S, Zhao Y, Ren M, Zhang J, Wang Y, Han L, et al. A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine granules for the treatment of menopausal symptom by stages. Menopause 2016;23:311–23.

78 Garcia J, Gonzaga F, Tan D, Ng T, Oei P, Chan C. Use of a multibotanical (Nutrafern) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. Menopause 2010;17:303–8.

79 Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progesterone combination hormone replacement therapy: a placebo-controlled study. Menopause 2003;10:29–36.
Variation in reported menopausal vasomotor symptoms

80 Geller S, Shulman L, Breen R, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156–66.

81 Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group. Clin Ther 1996;18:1093–105.

82 Good WR, John VA, Ramirez M, Higgins JE. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. Climacteric 1999;2:29–36.

83 Goodwin J, Green S, Mouinour C, Bearden J, Giguerre J, Jiang C, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: southwest Oncology Group Study 9626. J Clin Oncol 2008;26:1650–6.

84 Gordon PR, Kenwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:568–75.

85 Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823–30.

86 Grady D, Sawaya GF, Johnson KC, Koltun W, Hess R, Vittinghoff E, et al. MF101, a selective serotonin receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16:458–65.

87 Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337–45.

88 Guttuso T, McDermott MP, Su H, Kieburtz K. Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial. Obstet Gynecol 2008;112:109–15.

89 Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13:370–6.

90 Haines C, Lam P, Chung T, Cheng K, Leung P. A randomized, double-blind, placebo-controlled study of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 1996;24:177–84.

91 Hiltitch JR, Lewis J, Ross AH, Peter A, van Maris B, Franssen E, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 2000;34:143–53.

92 Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 2009;12:319–28.

93 Huang AJ, Phillips S, Schembi M, Vittinghoff E, Grady D. Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2015;125:1130–8.

94 Hudířa D, Posea C, Ceausu I, Rusu M. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. Eur Rev Med Pharmacol Sci 2003;7:117–25.

95 Jacobson JS, Troxel AB, Evans J, Klaas L, Vahdat L, Kinne D, et al. Randomized trial of black cohosh for the treatment of hot flushes in women with a history of breast cancer. J Clin Oncol 2001;19:2739–45.

96 Jenabi E, Shobeiri F, Hazavehei SMM, Roshanaei G. The effect of Valerian on the severity and frequency of hot flashes: A triple-blind randomized clinical trial. Women Health 2018;58:297–304.

97 Jenks BH, Iwahashi S, Nakagawa Y, Randlag K, Lee J, Carson WH, et al. A pilot study on the effects of 5-equol compared to soy isoflavones on menopausal hot flash frequency. J Women’s Health. 2012:21:674–82.

98 Jou H, Guthrie K, LaCroix A, Reed S, Ensrud K, Manson J, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058–66.

99 Jou HJ, Wu SC, Ling PY, Chu KS, Wu WH. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet 2008;102:44–9.

100 Kalay AY, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause 2007;14:233–64.

101 Khaodhiar L, Ricciotti HA, Li L, Pan W, Schickel M, Zhou J, et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009;15:24–34.

102 Kim DI, Jeong JC, Kim KH, Rho JJ, Choi MS, Yoon SH, et al. Acupuncture for hot flashes in perimenopausal and postmenopausal women: a randomised, sham-controlled trial. Acupuncture Med 2011;29:249–56.
Kim KH, Kang KW, Kim DI, Kim HJ, Yoon HM, Lee JM, et al. Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women—A multicenter randomized clinical trial. Menopause 2010;17:269–80.

Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114–22.

Kitanohara M, Yamamoto T, Masunaga S, Ohishi M, Komatsu Y, Nagase M. Effect of porcine placental extract on the mild menopausal symptoms of climacteric women. Climacteric 2017;20:144–50.

Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foadit JM, Bundred N, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG 2005;112:228–33.

LaCroix A, Freeman E, Larson J, Carpenter J, Joffe H, Reed S, et al. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012;73:361–8.

Lambert M, Thorup A, Hansen E, Jeppesen P. Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. PLoS One 2017;12:e0176590.

Langgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109:1109–14.

Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy versus placebo for treatment of menopausal symptoms in patients with early breast cancer: Eur J Cancer 2005;41:708–14.

Lefkowitch JH, Rezende A, Azevedo G, et al. Safety and efficacy of tibolone and estradiol cypionate in the treatment of hot flashes in breast cancer patients—A double-blind, randomized controlled trial. Ann Oncol 2013;24:969–75.

Lin S, Sun L, Lin J, Yang X, Zhang L, Qiao J, et al. Estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas 2007;57:361–9.

Lisà G, Razzini G, Musti M, Stivanello E, Petrucci C, Benedetti B, et al. Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcClimMaT). J Clin Oncol 2016;34:1795–802.

Liu JH, Reape KZ, Hatt HI. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012;119:78–84.

Liu ZM, Ho SC, Woo J, Chen YM, Wong C. Randomized controlled trial of whole soy and isoflavone daidzein on menopausal symptoms in equol-producing Chinese postmenopausal women. Menopause 2014;21:653–60.

Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—A double-blind, randomized study. Ann Oncol 2007;18:689–93.
177 Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189–96.

178 Secrete G, Chiechi L, Amadori A, Miceli R, Venturelli E, Valerio T, et al. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas 2004;47:11–20.

179 Sehatie Shafaei F, Monghafourvand M, Jafari M. Effect of education through support -group on early symptoms of menopause: a randomized controlled trial. J Caring Sci 2014;3:247–56.

180 Shamshad Begum S, Jayalakshmi HK, Vidyavathi HG, Gopakumar G, Abin I, Balu M, et al. A novel extract of fenugreek husk (FenuSMARTM) alleviates postmenopausal symptoms and helps to establish the hormonal balance: a randomized, double-blind. placebo-controlled study. Phytother Res 2016;30:1775–84.

181 Shoberi F, Jenabi E, Khatiban M, Hazavehei SMM, Roshanaei G. The effect of educational program on quality of life in menopausal women: a clinical trial. J Menopausal Med 2017;23:91–5.

182 Shulman LP, Yankov V, Uli K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/fevonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. [Erratum appears in Menopause 2002;9:385]. Menopause 2002;2002:195–207.

183 Simon J. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006;13:222–31.

184 Simon J, Bouchard C, Waldbaum A, Ulian W, Zborowski J, Snabes M. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109:588–96.

185 Simon J, Gaines T, LaGuardia K. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 2016;23:1214–21.

186 Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–35.

187 Simon JA, Stevens RE, Ayres SA, Phelps KV. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome. Climacteric 2001;4:19–27.

188 van der Sluijs C, Bensoussan A, Chang S, Baber R. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause 2009;16:336–44.

189 Sood R, Sood A, Wolf SL, Linquist BM, Liu H, Sloan JA, et al. Paced breathing compared with usual breathing for hot flashes. Menopause 2013;20:179–84.

190 Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003;102:823–34.

191 Speroff L, Gass M, Constantine G, Olivier S. Study I. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87.

192 Speroff L, Haney AF, Gilbert RD, Eillman H. Estradiol Acetate Investigator G. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause 2006;13:442–50.

193 Speroff L, Symons J, Kempfert N, Rowan J. Femhrt Study I. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383–90.

194 Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587–92.

195 St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001;8:17–26.

196 Steams V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827–34.

197 Steels E, Steele M, Harold M, Adams L, Coulson S. A double-blind, randomized, placebo-controlled trial evaluating safety and efficacy of an ayurvedic botanical formulation in reducing menopausal symptoms in otherwise healthy women. J Herbal Med 2018.

198 Steels E, Steele M, Harold M, Coulson S. Efficacy of a proprietary Trigonella foenum-graecum L. de-husked seed extract in reducing menopausal symptoms in otherwise healthy women: a double-blind, randomized, placebo-controlled study. Phyto Ther 2017;31:1316–22.

199 Sternfeld B, Guthrie K, Ensrud K, LaCroix A, Larson J, Dunn A, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014;21:330–8.

200 Stevenson JC, Durand G, Kahler E, Pertynski T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010;67:227–32.

201 Stowell D, Ulian W, Gass M, Qu Y, Muram D, Wong M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510–7.

202 Studd J, McCarthy K, Zamblera D, Burger H, Silberberg S, Wren B, et al. Efficacy and tolerance of Menerest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995;22:105–14.

203 Studd J, Pernel B, Marot I, Bringer J, Varin C, Tsouderos Y, et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group [Erratum appears in Lancet 1999 Aug 28;354 (9180):780]. Lancet 1999;353:1574–8.

204 Sulak PJ, Caulipel B, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progesterin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999;44:286–96.

205 Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26.

206 Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13:917–25.

207 Tannhaasamut P, Vichinsartvichai P, Pattanachaiyamont M, Techatraisak K, Dangrat C, Sardod P. Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. Climacteric 2015;18:79–85.

208 Tice JA, Ettinger B, Ensrud K, Wallace R, Cummings SR. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290:207–14.

209 Uebelhack R, Bloomer JR, Graubaum HJ, Busch R, Gruenwald J, Wenerme KD. Black cohosh and St. John's wort for climacteric complaints: A randomized trial. Obstet Gynecol 2006;107:247–55.
Variation in reported menopausal vasomotor symptoms

210 Utian W, Lederman S, Williams B, Vega R, Kolun W, Leonard T. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol 2004;103:245–53.

211 Utian W, Speroff L, Ellman H, Dart C. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause 2005;12:708–15.

212 Utian WH, Burry KA, Archer DF, Gallagher JC, Boyett RL, Guy MP, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Eslim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Eslim Study Group. Am J Obstet Gynecol 1999;181:71–9.

213 van der Sluijs CP, Bensoussan A, Chang S, Baber R. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause 2009;16:336–44.

214 van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause 2009;16:156–63.

215 Van Patten CL, Olivatto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–55.

216 Verhoeven MO, van der Moeren MI, van de Weijer PH, Verdegem PJ, van der Burgt LM, Kenemans P, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005;12:412–20.

217 Villa P, Amar ID, Bottoni C, Cipolla C, Dinoi G, Moruzzi MC, et al. The impact of combined nutraceutical supplementation on quality of life and metabolic changes during the menopausal transition: a pilot randomized study. Arch Gynecol Obstet 2017;296:791–801.

218 Vincent A, Barton DL, Mandrekar JN, Cha SS, Zais T, Wahnner-Roedler DL, et al. Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause 2007;14:45–52.

219 van Hagens C, Schiller P, Godbillion B, Osburg J, Klose C, Limprecht R, et al. Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. Climacteric 2012;15:358–67.

220 von Holst T, Salbach B. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas 2002;41:231–42.

221 Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010;28:634–40.

222 Wang CC, Cheng KF, Lo WM, Law C, Li L, Leung PC, et al. A randomized, double-blind, multiple-dose escalation study of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) for moderate to severe menopausal symptoms and quality of life in postmenopausal women. Menopause 2013;20:223–31.

223 Winther K, Reิน E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flashes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005;8:162–70.

224 Wong C, Yip BH, Gao T, Lam KYY, Woo DMS, Yip ALK, et al. Mindfulness-based stress reduction (MBSR) or Psychoeducation for the reduction of menopausal symptoms: a randomized. Controlled Clinical Trial. Sci Rep 2018;8:6609.

225 Wuttke W, Raus K, Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanol extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas 2006;55:583–591.

226 Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698–705.

227 Xi S, Mao L, Chen X, Bai W. Effect of health education combining diet and exercise supervision in Chinese women with perimenopausal symptoms: a randomized controlled trial. Climacteric 2017;20:151–6.

228 Xia Y, Zhao Y, Ren M, Zhang J, Wang Y, Chang Y, et al. A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing’e Fang) for hot flashes and quality of life in perimenopausal women. Menopause 2012;19:234–44.

229 Yang H, Yang J, Wen Z, Zha Q, Nie G, Huang X, et al. Effect of combining therapy with traditional chinese medicine-based psychotherapy and herbal medicines in women with menopausal syndrome: a randomized controlled clinical trial. Evid Based Complement Alternat Med 2012;2012:354145.

230 Zhong LL, Tong Y, Tang GW, Zhang ZI, Choi WK, Cheng KL, et al. A randomized, double-blind, controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in Hong Kong perimenopausal women. Menopause 2013;20:767–76.

231 Hunter MS, Liao KL. A psychological analysis of menopausal hot flushes. Br J Clin Psychol 1995;34(Pt 4):589–99.

232 Hunter M. The Women’s Health Questionnaire (WHQ): the development, standardisation and application of a measure of mid-aged women’s emotional and physical health. Qual Life Res 2000;9:733–8.

233 Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001;22:979–89.

234 Carpenter JS, Bakoyannis G, Otte JL, Chen CX, Rand KL, Woods N, et al. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales. Menopause 2017;24:877–85.

235 Hoga L, Rodolpho J, Goncalves B, Quirino B. Women’s experience of menopause: a systematic review of qualitative evidence. JBI Database System Rev Implement Rep 2015,13:250–337.

236 Im EO. Ethnic differences in symptoms experienced during the menopausal transition. Health Care Women Int 2009;30:339–55.

237 Prague JK, Dhillon WS. Neurokinin 3 receptor antagonism - the magic bullet for hot flushes? Climacteric 2017;20:505–9.

238 Nistor I, Bolognino D, Haier MC, Nagler E, van der Veen SN, Jager K, et al. Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrol Dial Transplant 2017;32:1268–73.

239 Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a ‘Core Outcome Set’—a practical guideline. Trials 2016;17:449.
